Method for eliciting an immune response to an immunogen
US-2015297711-A1 · Oct 22, 2015 · US
Nanostructure enhanced targeting (NSET) of inflammatory cells
US10821078B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10821078-B2 |
| Application number | US-201715637333-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jun 29, 2017 |
| Priority date | Jun 30, 2016 |
| Publication date | Nov 3, 2020 |
| Grant date | Nov 3, 2020 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention provides nanomaterials for the specific targeting of immune cells. Methods of treating cardiac disease and inflammatory disease are also described.
First claim
Opening claim text (preview).
The invention claimed is: 1. A method of targeting an agent to dendritic cells in a subject having or suspected of having cardiovascular disease, the method comprising administering to the subject a polymersome comprising block copolymers of polyethylene glycol) (PEG) and polypropylene sulfide) (PPS) incorporating or encapsulating a statin for the diagnosis or treatment of cardiovascular disease, wherein the polymersome targets dendritic cells within the subject. 2. The method of claim 1 , wherein the polymersome comprises a vesicular polymer membrane comprising PEG 17 -bl-PPS 30 . 3. The method of claim 1 , wherein the size of the polymersome is about 90 to about 150 nm in diameter, and wherein the statin is delivered to dendritic cells within the blood vessels of the subject and ameliorates at least one symptom of cardiovascular disease. 4. The method of claim 1 , wherein the cardiovascular disease comprises atherosclerotic lesions. 5. The method of claim 1 , wherein the polymersome does not contain a targeting ligand specific for dendritic cells. 6. The method of claim 1 , wherein the polymersomes increase the specific uptake of an agent by dendritic cells within the blood vessels by at least 20% as compared to the agent alone. 7. The method of claim 1 , the method further comprising: selecting a subject having or suspected of having atherosclerotic lesions prior to the administering step. 8. A method of targeting an agent to dendritic cells within atherosclerotic lesions in a subject having or suspected of having atherosclerotic lesions, the method comprising administering to the subject a polymersome comprising block copolymers of poly(ethylene glycol) (PEG) and polypropylene sulfide) (PPS), the polymersome incorporating or encapsulating a statin for the diagnosis or treatment of atherosclerotic lesions, wherein the polymersome targets dendritic cells within the subject. 9. The method of claim 8 , wherein the polymersome comprises PEG 17 -bl-PPS 30 . 10. The method of claim 8 , wherein the size of the polymersome is about 90 to about 150 nm in diameter, and wherein the agent is delivered to dendritic cells within the blood vessels of the subject and ameliorates at least one symptom of cardiovascular disease.
Assignees
Inventors
Classifications
Indocyanine green, i.e. ICG, cardiogreen · CPC title
Methine dyes, e.g. cyanine dyes · CPC title
containing sulfur · CPC title
Polysulfides · CPC title
having sulfur bound to carbon and hydrogen · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US10821078B2 cover?
- The present invention provides nanomaterials for the specific targeting of immune cells. Methods of treating cardiac disease and inflammatory disease are also described.
- Who is the assignee on this patent?
- Univ Northwestern
- What technology area does this patent fall under?
- Primary CPC classification A61K9/1273. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Nov 03 2020 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 1 related publication on this page (citations in our corpus or others sharing the same primary CPC).